Kymera Therapeutics (NASDAQ:KYMR) Stock Price Expected to Rise, HC Wainwright Analyst Says

Kymera Therapeutics (NASDAQ:KYMR) had its price objective upped by equities research analysts at HC Wainwright from $54.00 to $60.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would indicate a potential upside of 100.15% from the stock’s previous close.

Other research analysts have also recently issued reports about the stock. Guggenheim increased their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st. Leerink Partners reaffirmed an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a report on Friday, December 27th. Wells Fargo & Company raised shares of Kymera Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $38.00 to $57.00 in a research note on Monday, December 2nd. UBS Group reduced their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Finally, Stephens reiterated an “overweight” rating and issued a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $56.69.

Kymera Therapeutics Stock Down 15.2 %

Kymera Therapeutics stock opened at $29.98 on Friday. The stock has a market cap of $1.94 billion, a price-to-earnings ratio of -12.81 and a beta of 2.18. The business has a 50-day simple moving average of $39.21 and a 200 day simple moving average of $43.82. Kymera Therapeutics has a 52 week low of $29.22 and a 52 week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to analysts’ expectations of $14.81 million. On average, research analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, insider Ellen Chiniara sold 3,129 shares of the company’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at $2,288,985.50. This represents a 5.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 15.82% of the company’s stock.

Hedge Funds Weigh In On Kymera Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Blue Trust Inc. grew its position in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock worth $25,000 after buying an additional 270 shares during the period. State of Wyoming bought a new stake in Kymera Therapeutics during the fourth quarter worth about $45,000. GF Fund Management CO. LTD. purchased a new stake in Kymera Therapeutics in the fourth quarter worth about $55,000. KBC Group NV increased its stake in shares of Kymera Therapeutics by 53.8% during the fourth quarter. KBC Group NV now owns 2,151 shares of the company’s stock valued at $87,000 after purchasing an additional 752 shares in the last quarter. Finally, Quarry LP purchased a new position in shares of Kymera Therapeutics during the third quarter valued at approximately $95,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.